BMRN (Biotechnology) Stock Valuation & Fair Value Quality business at a reasonable price
BMRN (Biotechnology) trades at a blended P/E of 16.8, about 67% below its historical normal valuation, with a forward growth estimate of 39.1% and a PEG of 0.43.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is BMRN overvalued?
At a blended P/E of 16.8 versus its historical normal P/E of 51.0, BMRN trades about 67% below its typical valuation, with a PEG of 0.43 on 39.1% forward growth. tickerseer currently rates it quality business at a reasonable price.
What is BMRN's fair value and PEG?
BMRN trades at a blended P/E of 16.8 against a historical normal P/E of 51.0, a PEG of 0.43, and a forward growth estimate of 39.1%.
Has tickerseer's rating of BMRN changed?
tickerseer's rating has been quality business at a reasonable price since 2026-07-31.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.